ECSP085181A - Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares - Google Patents

Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares

Info

Publication number
ECSP085181A
ECSP085181A EC2008005181A ECSP085181A ECSP085181A EC SP085181 A ECSP085181 A EC SP085181A EC 2008005181 A EC2008005181 A EC 2008005181A EC SP085181 A ECSP085181 A EC SP085181A EC SP085181 A ECSP085181 A EC SP085181A
Authority
EC
Ecuador
Prior art keywords
prevention
treatment
derivatives
vascular diseases
same
Prior art date
Application number
EC2008005181A
Other languages
English (en)
Inventor
Margaret Forney Prescott
Walter Schuler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP085181A publication Critical patent/ECSP085181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Se proporcionan sistemas de administración de fármacos para la prevención y tratamiento de enfermedades proliferativas, particularmente enfermedades vasculares, comprendiendo dichos métodos rapamicina y derivados de rapamicina que tienen propiedades de inhibición de mTOR, opcionalmente en conjunto con uno o más co-agentes.
EC2008005181A 2002-01-10 2008-08-25 Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares ECSP085181A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34726402P 2002-01-10 2002-01-10

Publications (1)

Publication Number Publication Date
ECSP085181A true ECSP085181A (es) 2008-09-29

Family

ID=23363001

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008005181A ECSP085181A (es) 2002-01-10 2008-08-25 Sistema de administración de fármacos que comprende rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares

Country Status (19)

Country Link
US (5) US20050020614A1 (es)
EP (1) EP1465624A1 (es)
JP (1) JP2005514411A (es)
KR (1) KR20040076278A (es)
CN (1) CN1615137A (es)
AU (1) AU2003205586A1 (es)
BR (1) BR0306858A (es)
CA (1) CA2472198A1 (es)
CO (1) CO5601015A2 (es)
EC (1) ECSP085181A (es)
HU (1) HUP0402594A3 (es)
IL (1) IL162719A0 (es)
MX (1) MXPA04006731A (es)
NO (1) NO20043309L (es)
PL (1) PL369671A1 (es)
RU (3) RU2004124387A (es)
TW (2) TW200730152A (es)
WO (1) WO2003057218A1 (es)
ZA (1) ZA200405118B (es)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7713297B2 (en) * 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20050125054A1 (en) * 2000-12-22 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1842569A3 (de) * 2001-02-16 2010-03-03 Abbott Laboratories Vascular Enterprises Limited Implantate mit FK506
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US10441747B2 (en) * 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
EP1485042A1 (en) * 2002-03-18 2004-12-15 Medtronic AVE Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk of restenosis
AU2003250913A1 (en) * 2002-07-08 2004-01-23 Abbott Laboratories Vascular Enterprises Limited Drug eluting stent and methods of manufacture
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CN100349627C (zh) * 2002-09-06 2007-11-21 艾博特公司 含有水合抑制剂的医疗装置及其制备方法
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
EP1596895B1 (en) 2003-02-18 2009-02-04 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US8088404B2 (en) * 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
WO2005016396A1 (en) * 2003-08-13 2005-02-24 Poly-Med, Inc. Biocompatible controlled release coatings for medical devices and related methods
US20040254629A1 (en) * 2003-04-25 2004-12-16 Brian Fernandes Methods and apparatus for treatment of aneurysmal tissue
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
WO2005049021A1 (en) * 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
US7659244B2 (en) 2003-11-03 2010-02-09 Quest Pharmatech, Inc. Rapamycin peptides conjugates: synthesis and uses thereof
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
WO2005075003A1 (en) * 2004-01-21 2005-08-18 Medtronic Vascular Inc. Implantable medical devices for treating or preventing restenosis
BRPI0507030A (pt) * 2004-01-22 2007-06-05 Novartis Ag combinação de compostos orgánicos
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050220836A1 (en) * 2004-03-31 2005-10-06 Robert Falotico Drug delivery device
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US8163269B2 (en) * 2004-04-05 2012-04-24 Carpenter Kenneth W Bioactive stents for type II diabetics and methods for use thereof
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
RU2006144809A (ru) * 2004-05-17 2008-06-27 Новартис АГ (CH) Комбинация органических соединений
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US20060051338A1 (en) * 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
US20090041778A1 (en) * 2004-11-22 2009-02-12 Sukhatme Vikas P Methods And Compositions For The Treatment Of Graft Failure
US20060127443A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery
US20060129215A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
US20060204546A1 (en) * 2005-03-14 2006-09-14 Conor Medsystems, Inc. Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent
EP2327429B1 (en) * 2005-03-23 2014-09-17 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7252834B2 (en) * 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
BRPI0611021A2 (pt) * 2005-05-31 2010-08-10 Novartis Ag combinação de inibidores de hmg-coa redutase e inibidores de mtor
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070038176A1 (en) * 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
WO2007053578A2 (en) * 2005-10-31 2007-05-10 Amulet Pharmaceuticals, Inc. Multi-phasic nitric oxide and drug co-eluting stent coatings
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
WO2007067477A1 (en) * 2005-12-06 2007-06-14 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US20070203171A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
US20070224235A1 (en) * 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) * 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
CA2996768C (en) * 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US20080051335A1 (en) * 2006-05-02 2008-02-28 Kleiner Lothar W Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers
US7868531B2 (en) * 2006-05-05 2011-01-11 Brother International Corporation Carbon nanotube arrays for field electron emission
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US20080004695A1 (en) * 2006-06-28 2008-01-03 Abbott Cardiovascular Systems Inc. Everolimus/pimecrolimus-eluting implantable medical devices
US8771343B2 (en) * 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US9173733B1 (en) * 2006-08-21 2015-11-03 Abbott Cardiovascular Systems Inc. Tracheobronchial implantable medical device and methods of use
EP2056821A2 (en) * 2006-08-22 2009-05-13 Novartis AG Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
MX2009002260A (es) * 2006-08-28 2009-03-20 Wyeth Corp Cateter o desviacion implantable que permite el suministro gradual de agentes terapeuticos.
WO2008033711A2 (en) 2006-09-14 2008-03-20 Boston Scientific Limited Medical devices with drug-eluting coating
WO2008045184A1 (en) * 2006-10-05 2008-04-17 Boston Scientific Limited Polymer-free coatings for medical devices formed by plasma electrolytic deposition
JP5336382B2 (ja) * 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
WO2008131131A1 (en) * 2007-04-17 2008-10-30 Micell Technologies, Inc. Stents having biodegradable layers
US7976915B2 (en) * 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
CN101815540B (zh) * 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US8002823B2 (en) * 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) * 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
JP2010533563A (ja) 2007-07-19 2010-10-28 ボストン サイエンティフィック リミテッド 吸着抑制表面を有する内部人工器官
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) * 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
US8221822B2 (en) * 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
JP2010535541A (ja) * 2007-08-03 2010-11-25 ボストン サイエンティフィック リミテッド 広い表面積を有する医療器具用のコーティング
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US20090104240A1 (en) * 2007-10-19 2009-04-23 Abbott Cardiovascular Systems Inc. Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases
US20090118818A1 (en) * 2007-11-02 2009-05-07 Boston Scientific Scimed, Inc. Endoprosthesis with coating
US7938855B2 (en) * 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090118809A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Endoprosthesis with porous reservoir and non-polymer diffusion layer
US8029554B2 (en) * 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090155337A1 (en) * 2007-11-12 2009-06-18 Endologix, Inc. Method and agent for in-situ stabilization of vascular tissue
JP2011513220A (ja) * 2008-02-21 2011-04-28 ヴァトリックス・メディカル・インコーポレーテッド デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
WO2009131911A2 (en) 2008-04-22 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
EP2303350A2 (en) 2008-06-18 2011-04-06 Boston Scientific Scimed, Inc. Endoprosthesis coating
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
RU2380059C1 (ru) * 2008-08-19 2010-01-27 Екатерина Игоревна Шишацкая Покрытие стента
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8231980B2 (en) * 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8071156B2 (en) * 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
US20100274352A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scrimed, Inc. Endoprosthesis with Selective Drug Coatings
US8287937B2 (en) * 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
WO2011014563A1 (en) 2009-07-29 2011-02-03 Vatrix Medical, Inc. Tissue stabilization for heart failure
WO2011044455A1 (en) * 2009-10-09 2011-04-14 Vatrix Medical, Inc. In vivo chemical stabilization of vulnerable plaque
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
EP2531140B1 (en) * 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US20110257732A1 (en) * 2010-04-16 2011-10-20 Micell Technologies, Inc. Stents having controlled elution
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
CA2810842C (en) 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
EP2624834A4 (en) * 2010-10-04 2014-09-17 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
US9937255B2 (en) 2011-05-18 2018-04-10 Nectero Medical, Inc. Coated balloons for blood vessel stabilization
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US9220716B2 (en) * 2011-07-26 2015-12-29 Children's Medical Center Corporation Methods and compositions for the treatment of proliferative vascular disorders
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US20140094900A1 (en) * 2012-10-01 2014-04-03 Brigham Young University Compliant biocompatible device and method of manufacture
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014160358A1 (en) * 2013-03-14 2014-10-02 Thomas Cooper Woods Use of mir-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
US9522130B2 (en) 2013-03-14 2016-12-20 Thomas Cooper Woods Use of miR-221 and 222 lowering agents to prevent cardiovascular disease in diabetic subjects
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20210322651A1 (en) * 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
EP3515452B1 (en) 2016-09-22 2023-09-13 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
WO2018218182A1 (en) 2017-05-26 2018-11-29 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
CN109010931B (zh) * 2017-06-09 2022-03-11 上海微创医疗器械（集团）有限公司 介入医疗器械及阿非迪霉素的应用
WO2019104065A1 (en) * 2017-11-22 2019-05-31 Turrinii Pharmaceutical, Llc Anti-aging methods and compositions
CN111760174B (zh) 2018-03-14 2023-08-25 墨卡托医疗系统公司 用于局部药物递送的医疗器械和医疗方法
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3826649A4 (en) 2018-07-23 2022-07-20 Enclear Therapies, Inc. Methods of treating neurological disorders
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
US12576069B2 (en) * 2019-09-11 2026-03-17 Yale University Compositions and methods for treating slow-flow vascular malformations
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7213A (en) * 1850-03-26 Improvement in seed-planters
US82680A (en) * 1868-10-06 Rufus e
US27340A (en) * 1860-03-06 Improvement in steam-boilers
US123505A (en) * 1872-02-06 Improvement in wheel-plows
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NL1006553C2 (nl) * 1997-07-11 1999-01-12 Hoogovens Staal Bv Werkwijze voor het sturen (control) van een smelting reduction process.
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7208010B2 (en) * 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
JP2002530332A (ja) * 1998-11-20 2002-09-17 ザ ゼネラル ホスピタル コーポレーション 毛の成長を促進するためのピレスロイド化合物の使用
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US6805703B2 (en) * 2001-09-18 2004-10-19 Scimed Life Systems, Inc. Protective membrane for reconfiguring a workpiece
US7025734B1 (en) * 2001-09-28 2006-04-11 Advanced Cardiovascular Systmes, Inc. Guidewire with chemical sensing capabilities
IL163771A0 (en) * 2002-02-28 2005-12-18 Novartis Ag N-ä5-Ä4-(4-methyl-piperazino-methyl benzoylamidoÜ--2-methylphenylü-4-(3-pyridyl)-2-pyrimidine-amine coated stents

Also Published As

Publication number Publication date
BR0306858A (pt) 2004-11-03
TW200306826A (en) 2003-12-01
RU2004124387A (ru) 2005-06-10
ZA200405118B (en) 2005-06-21
HUP0402594A3 (en) 2006-01-30
TW200730152A (en) 2007-08-16
JP2005514411A (ja) 2005-05-19
EP1465624A1 (en) 2004-10-13
WO2003057218A1 (en) 2003-07-17
KR20040076278A (ko) 2004-08-31
CN1615137A (zh) 2005-05-11
US20030170287A1 (en) 2003-09-11
US20090043379A1 (en) 2009-02-12
US20050020614A1 (en) 2005-01-27
RU2008150750A (ru) 2010-06-27
US20090036352A1 (en) 2009-02-05
CA2472198A1 (en) 2003-07-17
MXPA04006731A (es) 2004-10-04
US20060127440A1 (en) 2006-06-15
RU2008107255A (ru) 2009-09-10
AU2003205586A1 (en) 2003-07-24
NO20043309L (no) 2004-08-09
IL162719A0 (en) 2005-11-20
HUP0402594A2 (hu) 2005-10-28
CO5601015A2 (es) 2006-01-31
PL369671A1 (en) 2005-05-02

Similar Documents

Publication Publication Date Title
MXPA04006731A (es) Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares.
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
LTC1765293I2 (lt) Farmacinės kompozicijos vaistų pristatymui ir būklių gydymo arba prevencijos būdai naudojant tas kompozicijas
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
ATE319478T1 (de) Screening-methode für inhibitoren von acrab und acrab-ähnlichen ausfluss-pumpen
DE602007012236D1 (de) Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
ATE347901T1 (de) Exendine zur glucagon suppression
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
WO2006002057A3 (en) Treatment of acne
ECSP055788A (es) Sistema de suministro de fármacos
WO2007030266A3 (en) Nitric oxide-releasing polymers derived from modified polyimines
WO2006097535A3 (en) Peptide agonists of the glucagon family with secretin like activity
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
WO2007050294A3 (en) Liquid dosage forms having enteric properties of delayed and then sustained release
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2008039409A3 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
ECSP045181A (es) Sistema de administración de fármacos que comprenden rapamicina y derivados de la misma para la prevención y tratamiento de enfermedades vasculares
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction